Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.
Peritoneal carcinomatosis and sarcomatosis (PCS) are short-term fatal conditions amenable only to palliative treatment. They are generally considered as a systemic disease at clinical presentation, and are resistant to standard treatments. However, there may be in the natural history a phase of loco-regional tumour spread during which the tumour may still be curable. Surgical treatment alone, or in combination with systemic chemotherapy, has yielded poor results in terms of survival and quality of life. One approach is cytoreductive surgery (CS) combined with the intraperitoneal administration of antiblastic agents. This may diminish any residual tumour following macroscopic excision and may overcome the pharmacokinetic limits of systemic chemotherapy. A further improvement in this multimodal approach may be achieved by the use of hyperthermic intraperitoneal intraoperative chemotherapy (HIIC). Results so far have been encouraging. However, series reported in the literature are relatively small and heterogeneous, and clinical and technical factors which include the selection of patients, optimal drugs dosage and temperature, evaluation of outcome and costs are still under discussion.
Pilati
P
P
Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Padova, Italy.
Rossi
C R
CR
Mocellin
S
S
Foletto
M
M
Scagnet
B
B
Pasetto
L
L
Lise
M
M
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D020360:Neoadjuvant Therapy; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D011859:Radiography; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D000970:Antineoplastic Agents